BioSpace News Archive

Phase Genomics, Inc., a global innovator for industry-leading genomic solutions, today announced the presentation of new data from the proximity ligation sequencing-based OncoTerra cytogenomics platform on the leading-edge AVITI next-generation sequencing system.

Verona Pharma plc, announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023’ at the SCRIP Awards in recognition of his exemplary leadership.

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the publication of the registrational Phase 2 FIREFLY-1 trial results evaluating the investigational agent tovorafenib in patients with BRAF-altered, relapsed or progressive pediatric low-grade glioma in Nature Medicine.

Virpax® Pharmaceuticals, Inc. announced that due to ongoing litigation it has accepted the resignation of Anthony P. Mack as CEO and Chairman effective immediately. The Board has appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman.

Novavax, Inc. today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company’s scale and structure announced last week.

Virpax ® Pharmaceuticals, Inc. today announced that it received a notice (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) on November 16, 2023 stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1).

Parexel today announced today announced it has been named “Best Contract Research Organization” in the Full-Service Provider category at the 19th Annual Scrip Awards.

Adlai Nortye Ltd. today announced the Completion of Patient Enrollment in Global Phase III Clinical Trial (BURAN) of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC.

GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced an increase of clinical cases in the United States using its GammaTile® Therapy in patients diagnosed with several brain tumor types.

Scilex Holding Company today announced that the U.S. Patent and Trademark Office has issued a second new patent, No. 11,786,455 (the ”Patent”).